OmniAb, Inc. reported $38M of revenue over the trailing twelve months, +67% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $38M (to Q2 2026). Net income: −$44M, trailing twelve months to Q2 2026. Free cash flow: −$18M, trailing twelve months to Q2 2026. Operating margin: −276%, trailing twelve months to Q2 2026.

OABIOmniAb, Inc.

Healthcare

$2.51+47% 1Y

$2.51

$1.3652 weeks$5.03

OABI as reported

OmniAb, Inc. reported $38M of revenue over the trailing twelve months, +67% on the year before. 8 reported series are charted on this page, each one as filed.

$38M

Revenue, trailing twelve months · to Q2 2026 · +67% against the twelve months before

Net income: −$44M
Net income · −30% year on year · trailing twelve months to Q2 2026
Free cash flow: −$18M
Free cash flow · −43% year on year · trailing twelve months to Q2 2026
Operating margin: −276%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OABI, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$38M	+67%	Q2 2026
Net income	−$44M	−30%	Q2 2026
EPS	−$0.36	−41%	Q2 2026
Operating margin	−276%	n/a	Q2 2026
Net margin	−251%	n/a	Q2 2026
ROE	−21%	n/a	Q2 2026
ROA	−19%	n/a	Q2 2026
Free cash flow	−$18M	−43%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.